J.P. Morgan: GSK CEO views oncology business as underappreciated

J.P. Morgan analysts, citing a call with GSK CEO Luke Miels, said he reiterated confidence in delivering GSK’s 2031 targets and expects upcoming updates at a medical congress to bolster investor confidence.